Dipyridamole Induced Ischemia and Biomarkers

Relationship Between the L-arginine Pathway Metabolites and Dipyridamole Stress Induced Transient Myocardial Ischaemia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03688815

Enrollment

Registered

2018-09-28

Start date

2009-01-01

Completion date

2017-01-01

Last updated

2018-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Attack, Ischemic Heart Disease

Brief summary

Analysis of certain biomarkers and transient myocardial perfusion deficit revealed by myocardial perfusion scintigraphy.

Detailed description

The prospectively enrolled patients were followed up to 5 years. Adverse major events (MI, stroke, death) suffered during follow-up were retrospectively analysed.

Interventions

DIAGNOSTIC_TESTmyocardial perfusion scintigraphy

Myocardial perfusion scintigraphy as it is described in the international literature.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. written informed consent. 2. clinical diagnosis of ischemic heart disease (IHD) -

Exclusion criteria

1. refused written informed consent. 2. lost data during follow-up \-

Design outcomes

Primary

Measure	Time frame	Description
Myocardial perfusion abnormality	5 year follow-up after MPS	Myocardial perfusion was quantified based on myocardial perfusion scintigraphy (MPS).

Countries

Hungary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026